Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: The TEAM Trial Experience

Histopathology

Volumn 55, Issue 5, 2009, Pages 587-593

  Faratian, Dana ^b,c   Kay, Charlene ^b,c   Robson, Tammy ^b   Campbell, Fiona M ^b   Grant, Margaret ^a   Rea, Dan ^a   Bartlett, John M S ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Biomarker; Clinical trial; ER; Image analysis; PR; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ACCURACY; ARTICLE; BREAST CANCER; CORRELATION COEFFICIENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SCORING SYSTEM;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 71049183065     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03419.x     Document Type: Article

References (31)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365 1687 1717.
2. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 9 45 53.
3. Jassem J. Intergroup Exemestane Study mature analysis: overall survival data. Anticancer Drugs 2008 19 (Suppl. 1 S3 S7.
4. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 2007 25 486 492.
5. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
6. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001 98 10869 10874.
7. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005 23 7483 7490.
8. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 2008 26 736 744.
9. Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. J. Clin. Oncol. 2008 26 5011 5013.
10. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004 6 R246 R251.
11. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst. 2005 97 1254 1261. (Pubitemid 41535366)
12. Arpino G, Green SJ, Allred DC et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 2004 10 5670 5676.
13. Grabau DA, Thorpe SM, Knoop A et al. Immunohistochemical assessment of oestrogen and progesterone receptors: correlations with the DCC method and clinical outcome in primary breast cancer patients. Breast 2000 9 208 217.
14. Kirkegaard T, Edwards J, Tovey S et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006 48 787 794.
15. Adams EJ, Green JA, Clark AH, Youngson JH. Comparison of different scoring systems for immunohistochemical staining. J. Clin. Pathol. 1999 52 75 77.
16. van Diest PJ, Weger DR, Lindholm J. Reproducibility of subjective immunoscoring of steroid receptors in breast cancer. Anal. Quant. Cytol. Histol. 1996 18 351 354.
17. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 2002 8 1323 1327.
18. Psyrri A, Yu Z, Weinberger PM et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin. Cancer Res. 2005 11 5856 5862.
19. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J. Surg. Res. 2008 147 99 107.
20. Aziz DC. Quantitation of estrogen and progesterone receptors by immunocytochemical and image analyses. Am. J. Clin. Pathol. 1992 98 105 111.
21. Esteban JM, Battifora H, Warsi Z, Bailey A, Bacus S. Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod. Pathol. 1991 4 53 57.
22. Esteban JM, Kandalaft PL, Mehta P, Odom-Maryon TL, Bacus S, Battifora H. Improvement of the quantification of estrogen and progesterone receptors in paraffin-embedded tumors by image analysis. Am. J. Clin. Pathol. 1993 99 32 38.
23. Fritz P, Hones J, Lutz D et al. Quantitative immunohistochemistry: standardization and possible application in research and surgical pathology. Acta Histochem. Suppl. 1989 37 9.
24. Turbin DA, Leung S, Cheang MC et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res. Treat. 2008 110 417 426.
25. Carrasco JL, Jover L. Estimating the generalized concordance correlation coefficient through variance components. Biometrics 2003 59 849 858.
26. Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. Am. J. Ment. Defic. 1981 86 127 137.
27. Molenberghs G, Burzykowski T, Alonso A, Buyse M. A perspective on surrogate endpoints in controlled clinical trials. Stat. Methods Med. Res. 2004 13 177 206.
28. Graham AD, Faratian D, Rae F, Thomas JS. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008 52 847 855.
29. Kyndi M, Sorensen FB, Knudsen H et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol. 2008 47 591 599.
30. Marinelli RJ, Montgomery K, Liu CL et al. The Stanford Tissue Microarray Database. Nucleic Acids Res. 2008 36 D871 D877.
31. Soderberg O, Leuchowius KJ, Gullberg M et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 2008 45 227 232.